The Goldman Sachs Group Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $625.00

Axon Enterprise (NASDAQ:AXON) had its price target lowered by research analysts at The Goldman Sachs Group from $720.00 to $625.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 57.13% from the company’s previous close.

Several other brokerages also recently weighed in on AXON. UBS Group reduced their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Royal Bank Of Canada dropped their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Morgan Stanley cut their price objective on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Robert W. Baird set a $800.00 price objective on Axon Enterprise in a research note on Wednesday, February 25th. Finally, Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a report on Tuesday, January 6th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $751.27.

Axon Enterprise Trading Up 6.7%

NASDAQ AXON traded up $24.90 during trading on Wednesday, hitting $397.77. The stock had a trading volume of 634,187 shares, compared to its average volume of 991,810. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $31.98 billion, a PE ratio of 261.32, a PEG ratio of 8.81 and a beta of 1.61. The firm has a 50 day moving average price of $473.50 and a 200 day moving average price of $572.61. Axon Enterprise has a twelve month low of $362.73 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter in the prior year, the company earned $2.08 earnings per share. The business’s quarterly revenue was up 38.5% on a year-over-year basis. As a group, equities research analysts forecast that Axon Enterprise will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the transaction, the chief executive officer owned 3,090,997 shares in the company, valued at $1,546,240,339.28. The trade was a 0.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Jennifer H. Mak sold 1,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 13,855 shares of company stock valued at $7,109,828 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently bought and sold shares of AXON. Newbridge Financial Services Group Inc. lifted its holdings in Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after buying an additional 14 shares during the last quarter. Vicus Capital increased its holdings in shares of Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 14 shares during the last quarter. Evergreen Capital Management LLC raised its position in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares in the last quarter. Blue Trust Inc. raised its position in shares of Axon Enterprise by 2.5% during the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC lifted its stake in Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 16 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Morgan Stanley reiterated a constructive view highlighting AI-driven growth as a compelling entry after the pullback; analyst note frames recent weakness as a buying opportunity tied to Axon’s software/AI expansion. Axon: AI-Driven Growth Outlook Creates Compelling Entry Point After Share Pullback
• Positive Sentiment: Axon announced three new AI tools at Axon Week (Axon Vision, Axon Assistant and expanded real‑time intelligence) that could accelerate recurring software revenue and deepen product stickiness with public‑safety customers. This is the primary operational catalyst supporting upside sentiment. Axon Tackles Public Safety’s Data Overload With Three New AI Tools
• Neutral Sentiment: Coverage pieces are flagging AXON as an oversold/turnaround candidate and as a play on unmanned aerial vehicle (UAV) exposure — useful framing for long‑term investors but not immediate price drivers. 2 Oversold Stocks Set for a Comeback and 1 We Brush Off
• Neutral Sentiment: AXON hit a 52‑week low, drawing attention from value/contrarian analysts — a data point that often attracts both bargain hunters and short‑term sellers. Axon stock hits 52-week low at 396.41 USD
• Negative Sentiment: Share weakness this week was driven by headlines about new legal risks tied to Axon’s HQ and related litigation, which prompted analyst price‑target cuts and increased uncertainty around expenses/legal liabilities. Axon Stock Plunged on Tuesday. Is This a Buying Opportunity?
• Negative Sentiment: Multiple outlets reported a >10% intraday decline amid analyst downgrades/price‑target trims and commentary that the stock lagged peers, which fed momentum selling. Why Axon (AXON) Shares Are Trading Lower Today
• Negative Sentiment: Broader market pressure — including rising U.S.‑Iran tensions and weaker macro data — weighed on tech and growth names, exacerbating AXON’s decline as investors fled higher‑multiple stocks. Why Axon Shares Are Sliding Tuesday?

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.